key: cord-0830456-ktoo408n authors: Chen, Yi; Wang, Guan; Ouyang, Liang title: Promising inhibitors targeting M(pro): an ideal strategy for anti-SARS-CoV-2 drug discovery date: 2020-08-27 journal: Signal Transduct Target Ther DOI: 10.1038/s41392-020-00291-8 sha: 0ea86f2f936607e5679dbbeab31e2e074a7551f1 doc_id: 830456 cord_uid: ktoo408n nan 11b exhibited strong inhibitory activities, with the potency of IC 50 = 0.053 ± 0.005 μM and 0.040 ± 0.002 μM, respectively. A further assay revealed that 11a and 11b also displayed good antiviral activities in Vero E6 cells (EC50 of 0.53 ± 0.01 μM and 0.72 ± 0.09 μM, respectively) with low cytotoxicity (CC50 is greater than 100 μM). Finally, pharmacokinetics and toxicity studies showed that 11a had better pharmacokinetics properties and no obvious toxicity in vivo. To elucidate the inhibitory mechanism of 11a and 11b, the crystal structure of M pro in complex with 11a (PDB code: 6LZE) and 11b (PDB code: 6M0K) was resolved, respectively, at a resolution of 1.5 Å. The structures show that 11a and 11b have a similar inhibitory binding mode. The aldehyde group forms a covalent force with Cys145 in the S1' region, whereas (S)-γ-lactam ring and indole group form intermolecular hydrogen bonds with S1 and S4 regions, respectively. A subtle difference between 11a and 11b in the S2 site was most probably due to the stereostructure and electronegativity difference between cyclohexyl and 3fluorophenyl groups. Notably, multiple water molecules also participated in the binding of protein-ligand complexes via hydrogen bonds. Overall, the binding modes of 11a and 11b with the M pro are consistent with those of compounds N1, N3, and N9 that are reported as wide spectrum inhibitors targeting coronavirus M pro . Taken together, with no vaccine or proven effective drug against SARS-COV-2, Dai W et al. designed and synthesized effective inhibitors based on the structure of the specific target M pro active site. Compound 11a is expected to become a promising clinical drug candidate. This research provides an effective strategy to design and discover anti-SARS-CoV-2 and even anti-coronavirus drugs targeting M pro . Before the emergence of specific drugs, the comprehensive application of drug design, medicinal chemistry, multidisciplinary technologies such as structural biology will help accelerate the development of anti-COVID-19 drugs. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/. © The Author(s) 2020 Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Safety perspectives on presently considered drugs for the treatment of COVID-19 Structure of M pro from SARS-CoV-2 and discovery of its inhibitors An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy This work was supported by grants from National Natural Science Foundation of China (Grant No. 81922064).